The CAI portfolio currently consists of CD34+ Hematopoietic Progenitor Stem Cells, Neural Stem Cells, Mesenchymal Stem Cells and Induced Pluripotent Stem Cells and iPSC-Derived lineages. Additional stem cell offerings are planned for the near future. CAI also provides high quality Human Dermal Fibroblasts (HDF), which can be used to generate induced pluripotents stem cells. iPSC are characterized by the ability to differentiate into numerous different cell types, representing diverse tissue.